International Center for Excellence in Research (ICER), Faculty of Medicine and Odontostomatology (FMOS), Faculty of Pharmacy (FAPHA), University Clinical Research Center (UCRC) at the University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Center for Polymers and Organic Solids, Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, California, USA.
Influenza Other Respir Viruses. 2024 Jul;18(7):e13343. doi: 10.1111/irv.13343.
The sero-epidemiological characteristics of SARS-CoV-2 infections in Mali are not yet well understood. This study assessed SARS-CoV-2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID-19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali.
A cross-sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti-Spike (anti-S) and anti-RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R-Studio was used for the statistical analysis. The chi-squared (χ) test was used to compare the proportions across different groups. Logistic regression models were used to elucidate factors associated with antibody responses.
The sex ratio for female-to-male was 3.6:1. The most representative groups were the 20-29-year-olds (28.9%, n = 1043) and the 30-39-year-olds (26.9%, n = 967). The COVID-19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1-9 years old) and male sex were associated with lower SARS-CoV-2 antibody responses, whereas COVID-19 vaccinations were associated with increased antibody responses.
This serosurvey demonstrated the high seroprevalence of SARS-CoV-2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.
马里 SARS-CoV-2 感染的血清流行病学特征尚不清楚。本研究评估了首都巴马科（COVID-19 的中心和震中）普通人群中 SARS-CoV-2 抗体血清阳性率和与抗体反应相关的因素，以评估大流行的规模，并为马里的控制策略改进做出贡献。
2022 年 9 月进行了横断面调查，以收集社会人口统计学信息、临床特征、合并症因素和血液样本。通过 ELISA 测定抗刺突（抗-S）和抗 RBD 抗体水平。共有 3601 名参与者在 REDCap 中注册。R-Studio 用于统计分析。卡方（χ）检验用于比较不同组之间的比例。逻辑回归模型用于阐明与抗体反应相关的因素。
女性与男性的性别比为 3.6:1。最具代表性的群体是 20-29 岁（28.9%，n=1043）和 30-39 岁（26.9%，n=967）。参与者中的 COVID-19 疫苗接种率为 35.8%，疫苗来自 Covishield AstraZeneca（13.4%）、Johnson & Johnson（16.7%）、Sinovac（3.9%）和 BioNTech Pfizer（1.8%）。总体而言，研究人群中 S 蛋白和 RBD 抗体的血清阳性率非常高（分别为 98%和 97%）。年轻人（1-9 岁）和男性等因素与 SARS-CoV-2 抗体反应较低有关，而 COVID-19 疫苗接种与抗体反应增加有关。
这项血清学调查表明，SARS-CoV-2 抗体的血清阳性率很高，并强调了影响抗体反应的因素，同时清楚地表明马里对大流行的低估。
